Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- Immunofixation electrophoresis is mainly an exclusion tool in suspected ATTR-CM, not a confirmation test.
- A negative result lowers concern for an overt monoclonal process, but it doesn’t confirm ATTR-CM.
- A positive result redirects the workup toward hematology and tissue typing; it doesn’t by itself settle AL amyloidosis versus ATTR.
- Immunofixation electrophoresis should be interpreted together with serum free light chain testing and the clinical phenotype to guide subsequent diagnostic investigations.
Role of Immunofixation Electrophoresis in the Diagnostic Evaluation
Serum and urine immunofixation electrophoresis plays an important role early in the diagnostic evaluation of suspected ATTR-CM by looking for a monoclonal protein that would raise suspicion toward AL amyloidosis or another plasma-cell process, rather than confirming transthyretin disease itself. It’s part of the same exclusion logic that frames the screening sequence.
Why It Is an Exclusion Test, Not a Confirmation Test
That makes immunofixation electrophoresis most useful for exclusion. A negative result lowers concern for an overt monoclonal process, but it doesn’t prove ATTR-CM, establish cardiac involvement, or define severity. A positive result doesn’t by itself settle AL amyloidosis versus ATTR and has to be interpreted inside the broader monoclonal-protein workup.
Clinical Implications of Immunofixation Electrophoresis Results
Immunofixation electrophoresis results help determine the subsequent diagnostic pathway. A negative immunofixation electrophoresis alongside negative serum free light chains and a compatible phenotype supports a noninvasive bone-avid imaging pathway, whereas a monoclonal band redirects the patient toward hematology and tissue typing before any ATTR-directed conclusion. This step is critical in determining whether a noninvasive confirmation is appropriate or whether tissue confirmation is required.
Where Immunofixation Electrophoresis Fits in the Panel
In practice, immunofixation electrophoresis should be interpreted together with serum free light chain testing, phenotype assessment, and complementary imaging. Its clinical value lies in preventing premature ATTR-directed conclusions before the amyloid subtype has been confirmed.
Clinical Decision Point
A negative immunofixation electrophoresis result supports continued evaluation using a non-biopsy diagnostic pathway when interpreted together with negative serum free light chain studies, a compatible clinical phenotype, and concordant bone-avid scintigraphy. A positive result should prompt consideration towards tissue biopsy with amyloid typing and hematology input rather than an imaging-only conclusion.
Frequently Asked Questions
What’s the role of immunofixation electrophoresis in suspected ATTR-CM?
Evidence of a monoclonal protein would shift the pathway toward AL amyloidosis or another plasma-cell disorder.
Can a negative immunofixation electrophoresis confirm ATTR-CM?
No. It lowers concern for an overt monoclonal process, but it doesn’t confirm transthyretin disease or establish cardiac involvement.
What does a positive immunofixation electrophoresis mean?
It redirects the workup toward hematology and tissue typing. It doesn’t by itself settle AL amyloidosis versus ATTR because a monoclonal protein and ATTR amyloid can coexist.
How is immunofixation electrophoresis used together with serum free light chains?
Serum free light chain testing and immunofixation electrophoresis provide complementary diagnostic information. The serum free light chain assay provides a sensitive quantitative assessment of free light chain abnormalities, while immunofixation electrophoresis confirms and characterizes the monoclonal protein. Both results should be interpreted in conjunction with the clinical phenotype and other diagnostic findings.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.